Terminated PHASE2/PHASE3 INTERVENTIONAL NCT00463723

Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty

Sponsor: Sucampo Pharmaceuticals, Inc.

Updated 4 times since 2017 Last updated: Apr 18, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Sucampo Pharmaceuticals, Inc.

Constipation · Phase PHASE4 · Sep 2012

More terminations from Sucampo Pharmaceuticals, Inc.

A PHASE2/PHASE3 clinical study on Penetrating Keratoplasty, this trial is terminated or withdrawn. The trial is conducted by Sucampo Pharmaceuticals, Inc. and has accumulated 4 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sucampo Pharmaceuticals, Inc.
University Hospital Freiburg

Data source: University Hospital Freiburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.